Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=pp405,pyrilutamide,sm04554

Side-by-side comparison of PP405, Pyrilutamide, SM04554
Identity
	PP405	Pyrilutamide	SM04554
Class	Investigational topical small molecule; inhibitor of the mitochondrial pyruvate carrier (MPC)	Investigational topical nonsteroidal androgen-receptor antagonist	Investigational topical small-molecule modulator of Wnt signalling
Also listed as	PP405 topical gel, PP405-2001	KX-826, KX826, Pyrilutamide topical	Dalosirvat, SM-04554
Molecular formula	Not recorded	Not recorded	Not recorded
Molecular weight	Not recorded	Not recorded	Not recorded
CAS	Not recorded	Not recorded	Not recorded
PubChem CID	Not recorded	Not recorded	Not recorded
Sequence length	Not recorded	Not recorded	Not recorded
Data caveat	None recorded	None recorded	None recorded
United States regulatory status
Status	Investigational	Investigational	Investigational
FDA application	None recorded	None recorded	None recorded
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Follicle stem-cell reactivation	Topical androgen-receptor blockade	Wnt-pathway modulation
Proposed mechanism	Inhibits the mitochondrial pyruvate carrier (MPC), shifting cellular metabolism and activating dormant follicle stem cells in laboratory and early human biopsy work. This is a proposed mechanism with early human biomarker support, not proof of hair regrowth.	A nonsteroidal androgen-receptor antagonist applied to the scalp, intended to reduce androgen signalling in follicle cells. The clinical advantage over existing treatments is not established.	Proposed activation of Wnt/beta-catenin signalling in the follicle, promoting follicle proliferation. The trial protocol itself flags theoretical pathway-related risks.
Human evidence	Phase 1 and a completed Phase 2a trial in androgenetic alopecia; a Phase 2 trial in women is registered. Therapept has not indexed a peer-reviewed primary publication of the Phase 2a results.	Phase 2 trials in men and women and a Phase 3 trial in Chinese men are registered; the Phase 2 studies are listed as completed. No approved product.	Phase 1 and Phase 2 trials were registered and completed. Therapept did not identify an active later-stage registration or an approved product at review.
Evidence tier	Phase 2 trials registered or reported	Phase 3 trials registered or reported	Phase 2 trials registered or reported
Known safety concerns	Phase 1 reported the product was well tolerated with no detectable systemic absorption, per the sponsor. Phase 2a safety results are not available here as a peer-reviewed report. Long-term safety is unknown.	Topical androgen-receptor blockade may still produce systemic effects; the trials are designed to measure this. Phase 3 safety data are not available here as a peer-reviewed report. Long-term safety is unknown.	The trial protocol notes theoretical risks of Wnt pathway modulation, including unwanted hair growth and skin lesions. Those are mechanistic concerns, not observed human findings in the indexed record. Long-term safety is unknown.
Evidence gaps	Peer-reviewed Phase 2a efficacy and safety results. Durability after treatment stops. Phase 3 confirmation and any regulatory decision.	Peer-reviewed Phase 3 efficacy and safety results. Whether topical delivery avoids meaningful systemic androgen blockade. Durability and any regulatory decision.	Peer-reviewed efficacy results from the Phase 2 programme. Current development status. Long-term safety of Wnt modulation in skin.
Head-to-head evidence	No head-to-head trial against minoxidil or any other hair-loss treatment has been published.	No published head-to-head trial against finasteride or minoxidil.	No published head-to-head trial against minoxidil or any other treatment.
Named pathways	Mitochondrial pyruvate carrier · Lactate dehydrogenase · Follicle stem-cell activation · Telogen-to-anagen transition	Androgen receptor · DHT signalling · Follicular miniaturisation	Wnt/beta-catenin signalling · Follicle proliferation · Hair cycle
Evidence on file
Records	1Open evidence file	2Open evidence file	1Open evidence file
Human-interventional records	1	2	1
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	0
Regulatory documents	0	0	0
Earliest indexed	2024	2022	2019
Latest indexed	2024	2024	2019

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.